**Table 1.** *Characteristics of the ExoMeth development cohort.*

|  |  |  |
| --- | --- | --- |
|  | Biopsy Negative: | Biopsy Positive |
| **Collection Centre:** |  |  |
| NNUH, n (%) | 68 (88) | 113 (94) |
| SJH, n (%) | 9 (12) | 7 (6) |
| **Age:** |  |  |
| minimum | 42.00 | 53.00 |
| median (IQR) | 66.00 (59.00, 71.00) | 69.50 (65.00, 76.00) |
| mean (sd) | 65.70 ± 8.53 | 69.97 ± 7.44 |
| maximum | 82.00 | 86.00 |
| **Serum PSA (ng/mL):** |  |  |
| minimum | 0.20 | 3.60 |
| median (IQR) | 6.70 (4.20, 8.80) | 10.05 (6.90, 18.20) |
| mean (sd) | 7.44 ± 5.59 | 17.50 ± 18.82 |
| maximum | 30.30 | 95.90 |
| **Prostate Size (DRE Estimate):** |  |  |
| Small, n (%) | 14 (18) | 12 (10) |
| Medium, n (%) | 29 (38) | 56 (47) |
| Large, n (%) | 22 (29) | 37 (31) |
| Unknown, n (%) | 12 (16) | 15 (12) |
| **Gleason Score:** |  |  |
| 0, n (%) | 77 (100) | N/A |
| 6, n (%) | N/A | 24 (20) |
| 3+4, n (%) | N/A | 42 (35) |
| 4+3, n (%) | N/A | 23 (19) |
| ≥ 8, n (%) | N/A | 31 (26) |